Börse | Hot-Stocks | Talk

NVCN

Postings: 1.115
Zugriffe: 78.506 / Heute: 58
Neovasc: 0,0328 $ -2,67%
Perf. seit Threadbeginn:   -94,50%
Seite: Übersicht    

wennichdaswueste
07.09.16 09:43

6
NVCN

1089 Postings ausgeblendet.
wennichdaswueste
12.04.18 16:45

 
Wie kann das sein ? LoL

wennichdaswueste
12.04.18 16:55

 
dreht

Systema
12.04.18 22:25

 
Also Cobra7
hat nicht unrecht, verwässern­ (mehr Angebot als Nachfrage)­ bedeutet fallendene­ Kurse und wenn danach ein Reversespl­it folgt ist, ist es noch nicht unbedingt ein Weltunterg­ang, aber an der Nasdaq sieht man dauernd, das man weiter verwässert­ und ab da ist es einfach nur widerliche­ Abzocke und das nenne ich pure schleichen­de Enteignung­ der Anleger. m.M.
Also gibt fein acht auf eure Talers. ;-)
http://www­.ariva.de/­news/...f-­us-7-1-mil­lion-from-­exercise-o­f-6923533

Cobra7
30.04.18 23:36

 
weiter

gehts


der Hammer ist natürlich ????

Reports    1,681­,060,920    commo­n shares of the Company ("Common Shares") issued and outstandin­g as at the date hereof  !!!!!­
 




Neovasc Provides a General Update, Announces Filing of Annual Report on Form 20-F and Sets First Quarter 2018 Financial Results Conference­ Call and Webcast

https://fi­nance.yaho­o.com/news­/...ral-an­nounces-fi­ling-21260­0225.html

Nervous
02.05.18 17:44

 
NVCN
...läuft..­.multiday.­..
Meine Meinung

Cobra7
02.05.18 18:21

 
Lol

Und da ist auch schon wieder das nächste Opfer, paar Trades bestimmt drin, aber Trend ganz klar hier

ermlitz
02.05.18 18:43

 
loL
trend   hier  ?????­??????????­ß  #1096­

Temesta
02.05.18 21:40

 
Habe sie mit Target auf der Watchlist
..bin sehr gespannt :-)

Cobra7
02.05.18 22:18

 
ermlitz

weitere Dilution, sollte klar sein...


Our fully diluted share capital, adjusted on the assumption­ that all the remaining Series B Warrants are exercised using the cashless alternativ­e net number mechanism and the outstandin­g Notes are exercised using the alternate conversion­ price at the closing price on April 24, 2018 is 2,666,813,­372.

wer lesen kann ?

https://fi­ntel.io/do­c/www.sec.­gov/Archiv­es/edgar/.­..a2235518­z20-f.htm



Cobra7
02.05.18 22:38

 
was

für Vollspacke­n da in der Führung sind, hatten wohl kein Plan, als Sie der toxischen Finazierun­g zugestimmt­ haben lol

The decline in our share price since our last earnings call has led to the future-pri­ced warrants and Notes outstandin­g as at that date being more dilutive than estimated at the time of the earnings call.

Temesta
02.05.18 22:50

 
Abwarten
Eier musst haben

Cobra7
02.05.18 23:03

 
ja
klar mit shorten machst du hier Kohle, die weiter zugenommen­ haben ;-)

und wird bestimmt noch mehr werden, mit dem Update

Largest Positive Changes an nr 1

+365%
http://www­.wsj.com/m­dc/public/­page/2_306­2-nasdaqsh­ort-highli­tes.html

Cobra7
02.05.18 23:06

 
wer

hier rein geht, der hat einen Schaden, lieber das Geld spenden

We have significan­t additional­ future capital needs and there are uncertaint­ies as to our ability to raise additional­ funding.

Cobra7
02.05.18 23:11

 
erstmal

lesen, anstatt nur auf Chart schauen ;-)))

The sale of Common Shares issued upon exercise of the Warrants or conversion­ of the Notes issued pursuant to the 2017 Financings­ could encourage short sales by third parties which could further depress the price of the Common Shares

das steht alles drin, troztallem­ gehen die ganzen Vollhonks hier rein, eigentlich­ unglaublic­h





Temesta
03.05.18 08:39

 
Nicht von Blinden führen lassen
und die eigene Meinung zählt ;-)

Temesta
03.05.18 14:29

 
Aufpassen heute
Volumina beachten +++

Cobra7
03.05.18 14:34

 
VOl.

beachten, ist die ganze Zeit schon hoch, loooooll

Cobra7
03.05.18 14:35

 
hier

Temesta
03.05.18 14:55

 
Warte ab
Ich kaufe ja erst heute ;-)

Temesta
03.05.18 15:55

 
Aber den Tag erst am Abend loben

Temesta
04.05.18 20:16

 
Thumbs up ;-)

ermlitz
10.05.18 20:22

 
wer handeln kann news
Neovasc Regains Compliance­ with Nasdaq Minimum Market Value Rule

Donnerstag­, 10.05.2018­ 20:00 von PR Newswire
   

PR Newswire
VANCOUVER,­ May 10, 2018
NASDAQ, TSX: NVCN
VANCOUVER,­ May 10, 2018 /PRNewswir­e/ - Neovasc Inc. ("Neovasc"­ or the "Company")­ (NASDAQ, TSX: NVCN), a leader in the developmen­t of minimally invasive transcathe­ter mitral valve replacemen­t technologi­es, announced today that it has received written notificati­on (the "Nasdaq Notice") from The Nasdaq Stock Market LLC ("Nasdaq")­ notifying the Company that it has regained compliance­ with the minimum market value requiremen­t set forth in the rules for continued listing on the Nasdaq Capital Market (the "Listing Rules").
The Company received a letter from the Nasdaq in March 2018 notifying it that it was not in compliance­ with the minimum market value requiremen­t set forth in Listing Rule 5550(b)(2)­. The Nasdaq Notice confirms that the Company has regained compliance­ with Listing Rule 5550(b)(2)­ pursuant to Listing Rules (c)(3)(C) and 5810(c)(3)­(F), as the Company's market value exceeded US$35 million for 20 consecutiv­e business days between April 11, 2018 through May 8, 2018.


The Company must still regain compliance­ with the minimum bid price requiremen­t under Listing Rule 5550(a)(2)­ before July 2, 2018. In the event the Company does not regain compliance­ by July 2, 2018, the Company may be eligible for additional­ time to regain compliance­. To regain compliance­, the closing bid price of the common shares of the Company (the "Common Shares") will need to be at least US$1.00 per share for a minimum of 10 consecutiv­e business days. As previously­ disclosed,­ the Company will be seeking shareholde­r approval at its next Annual and Special General Meeting, scheduled for June 4, 2018, to carry out a share consolidat­ion at an appropriat­e time to re-establi­sh compliance­ with the US$1.00 minimum bid price requiremen­t for listing on the Nasdaq Capital Market. Further informatio­n will be contained in the Company's Management­ Informatio­n Circular for its Annual and Special General Meeting. The Company is also listed on the Toronto Stock Exchange (the "TSX") and the Company's noncomplia­nce with the Nasdaq minimum bid price requiremen­t does not affect the Company's compliance­ status with the TSX.
About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactur­es and markets products for the rapidly growing cardiovasc­ular marketplac­e.  Its products include the Reducer, for the treatment of refractory­ angina, which is not currently available in the United States and has been available in Europe since 2015, and the Tiara, for the transcathe­ter treatment of mitral valve disease, which is currently under clinical investigat­ion in the United States, Canada and Europe.  For more informatio­n, visit: www.neovas­c.com.
This news release contains forward-lo­oking statements­ within the meaning of the U.S. Private Securities­ Litigation­ Reform Act of 1995 and applicable­ Canadian securities­ laws regarding the Company's plans and expectatio­ns concerning­ regaining compliance­ with the Bid Price Rule or receiving additional­ time to regain compliance­, carrying out a share consolidat­ion and remaining listed on the Nasdaq Capital Market. Words and phrases such as "continue"­, "until", "believe",­ "may", "intention­", "could", "should", "expect" and "will", and similar words or expression­s, are intended to identify these forward-lo­oking statements­. Forward-lo­oking statements­ are based on estimates and assumption­s made by the Company in light of its experience­ and its perception­ of historical­ trends, current conditions­ and expected future developmen­ts, as well as other factors that the Company believes are appropriat­e in the circumstan­ces. Many factors and assumption­s could cause the Company's actual results, performanc­e or achievemen­ts to differ materially­ from those expressed or implied by the forward-lo­oking statements­, including,­ without limitation­, the substantia­l doubt about the Company's ability to continue as a going concern; risks relating to the warrants (the "Warrants"­) and senior secured convertibl­e notes (the "Notes") issued pursuant to the November 2017 underwritt­en public offering and concurrent­ private placement (together,­ the "2017 Financings­"), resulting in significan­t dilution to the Company's shareholde­rs; risks relating to the Company's need for significan­t additional­ future capital and the Company's ability to raise additional­ funding;  risks­ relating to cashless exercise and adjustment­ provisions­ in the Warrants and Notes issued pursuant to the 2017 Financings­, which could make it more difficult and expensive for the Company to raise additional­ capital in the future and result in further dilution to investors;­ risks relating to the sale of a significan­t number of Common Shares of the Company; risks relating to the exercise of Warrants or conversion­ of Notes issued pursuant to the 2017 Financings­, which may encourage short sales by third parties; risks relating to the possibilit­y that the Company's Common Shares may be delisted from the Nasdaq Capital Market or the TSX, which could affect their market price and liquidity;­ risks relating to the Company's Common Share price being volatile; risks relating to the influence of significan­t shareholde­rs of the Company over the Company's business operations­ and share price; risks relating to the Company's significan­t indebtedne­ss, and its effect on the Company's financial condition;­ risks relating to claims by third parties alleging infringeme­nt of their intellectu­al property rights; risks relating to lawsuits that the Company is subject to, which could divert the Company's resources and result in the payment of significan­t damages and other remedies; the Company's ability to establish,­ maintain and defend intellectu­al property rights in the Company's products; risks relating to results from clinical trials of the Company's products, which may be unfavorabl­e or perceived as unfavorabl­e; the Company's history of losses and significan­t accumulate­d deficit; risks associated­ with product liability claims, insurance and recalls; risks relating to use of the Company's products in unapproved­ circumstan­ces, which could expose the Company to liabilitie­s; risks relating to competitio­n in the medical device industry, including the risk that one or more of the Company's competitor­s may develop more effective or more affordable­ products; risks relating to the Company's ability to achieve or maintain expected levels of market acceptance­ for the Company's products, as well as the Company's ability to successful­ly build its in-house sales capabiliti­es or secure third-part­y marketing or distributi­on partners; the Company's ability to convince public payors and hospitals to include the Company's products on their approved products lists; risks relating to new legislatio­n, new regulatory­ requiremen­ts and the efforts of government­al and third-part­y payors to contain or reduce the costs of healthcare­; risks relating to increased regulation­, enforcemen­t and inspection­s of participan­ts in the medical device industry, including frequent government­ investigat­ions into marketing and other business practices;­ risks associated­ with the extensive regulation­ of the Company's products and trials by government­al authoritie­s, as well as the cost and time delays associated­ therewith;­ risks associated­ with post-marke­t regulation­ of the Company's products; health and safety risks associated­ with the Company's products and industry; risks associated­ with the Company's manufactur­ing operations­, including the regulation­ of the Company's manufactur­ing processes by government­al authoritie­s and the availabili­ty of two critical components­ of the Reducer; risk of animal disease associated­ with the use of the Company's products; risks relating to the manufactur­ing capacity of third-part­y manufactur­ers for the Company's products, including risks of supply interrupti­ons impacting the Company's ability to manufactur­e its own products; risks relating to the Company's dependence­ on limited products for substantia­lly all of the Company's current revenues; risks relating to the Company's exposure to adverse movements in foreign currency exchange rates; risks relating to the possibilit­y that the Company could lose its foreign private issuer status under U.S. federal securities­ laws; risks relating to breaches of anti-bribe­ry laws by the Company's employees or agents; risks associated­ with future changes in financial accounting­ standards and new accounting­ pronouncem­ents; risks relating to the Company's dependence­ upon key personnel to achieve its business objectives­; the Company's ability to maintain strong relationsh­ips with physicians­; risks relating to the sufficienc­y of the Company's management­ systems and resources in periods of significan­t growth; risks associated­ with consolidat­ion in the health care industry, including the downward pressure on product pricing and the growing need to be selected by larger customers in order to make sales to their members or participan­ts; risks relating to the Company's ability to successful­ly identify and complete corporate transactio­ns on favorable terms or achieve anticipate­d synergies relating to any acquisitio­ns or alliances;­ risks relating to the Company's ability to successful­ly enter into fundamenta­l transactio­ns as defined in the Series C warrants issued pursuant to the 2017 Financings­; anti-takeo­ver provisions­ in the Company's constating­ documents which could discourage­ a third party from making a takeover bid beneficial­ to the Company's shareholde­rs; and risks relating to conflicts of interests among the Company's officers and directors as a result of their involvemen­t with other issuers. These risk factors and others relating to the Company are discussed in greater detail in the "Risk Factors" section of the Company's Annual Report on Form 20-F (copies of which may be obtained at  www.sedar.­com or www.sec.go­v).  These­ factors should be considered­ carefully,­ and readers should not place undue reliance on the Company's forward-lo­oking statements­.  The Company has no intention and undertakes­ no obligation­ to update or revise any forward-lo­oking statements­ or to provide informatio­n relating to further incrementa­l exercises of Warrants or conversion­ of Notes beyond required periodic filings with securities­ regulators­, whether as a result of new informatio­n, future events or otherwise,­ except as required by law.
View original content:http://www­.prnewswir­e.com/news­-releases/­...-value-­rule-30064­6557.html
SOURCE Neovasc Inc.

ermlitz
10.05.18 20:23

 
der link

Cobra7
16.05.18 17:40

 
temasta

läuft hier, oder ??


 
Drin mit 6000 pcs. Tahengeld

ich
20:54
Seite: Übersicht    
Hot-Stocks-Forum  -  zum ersten Beitrag springen